Full-Time
Updated on 6/12/2025
AI platform for healthcare coordination
$194.2k - $225.5k/yr
Mid, Senior
Remote in USA
Viz.ai uses artificial intelligence to improve patient care coordination in healthcare. Its main product, the Viz.ai Intelligent Care Coordination Platform, helps medical teams communicate effectively and provides real-time alerts for conditions like strokes. The platform stands out by integrating with existing electronic health records and automating critical imaging processes, which leads to faster treatment decisions. The goal of Viz.ai is to enhance patient outcomes and hospital efficiency while ensuring the security of patient data.
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$291.5M
Headquarters
San Francisco, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Health, dental, & vision insurance
401K retirement plan
Generous vacation time
Paid parental leave
Monthly wellness days
Professional development stipend
Viz.ai, a leader in AI-driven imaging and care coordination, has announced a collaboration with Novartis to create specialized AI workflows within the Viz Oncology Suite.
New evidence from the largest prospective evaluation of stroke AI imaging further validates Brainomix 360 Stroke impact on mechanical thrombectomy, expanding patient access across networks to the life-changing treatmentThe Oxford -based pioneer continues to drive cutting-edge research with its novel biomarkers, forging partnerships with world-leading stroke institutions across the US and EuropeOXFORD, England and CHICAGO, May 29, 2025 /PRNewswire/ -- Brainomix, a global leader in AI-powered imaging solutions in stroke and lung fibrosis, presented a series of new studies at the European Stroke Organisation Conference (ESOC) in Helsinki, solidifying the position of its market-leading Brainomix 360 Stroke as the most clinically validated stroke AI imaging solution.Gary Ford (Professor of Stroke Medicine at Oxford University, and Chief Executive of Health Innovation Oxford & Thames Valley) presented new and expanded results from the largest prospective evaluation of stroke AI imaging software, showing that the use of Brainomix 360 Stroke was associated with an increase in mechanical thrombectomy rates across evaluation sites. The impact was particularly significant in primary stroke centers (104% increase), but was also observed in comprehensive stroke centers (73% increase), representing a network-wide benefit from Brainomix 360 Stroke to expand patient access to the life-changing procedure.Dr Albert Yoo (Texas Stroke Institute) presented results from a research collaboration between Brainomix and the TESLA Trial team, whose randomized study was originally published in JAMA in September 2024. In this new analysis of the trial data, Brainomix 360 Stroke was used to estimate the ischemic core volume and degree of hypoattenuation on the non-contrast CT (NCCT) scans taken upon admission for the 276 large vessel occlusion (LVO) patients included in the original study. The results showed that both ischemic core volume and the degree of hypoattenuation (as measured by net-water-uptake) modified the effect of mechanical thrombectomy and should therefore be considered when assessing suitability of endovascular treatment in patients with large core ischemic stroke.Building on its track record of cutting-edge stroke imaging research, Brainomix also presented a new study with leading academic clinicians from the Mayo Clinic and West Virginia University, exploring brain frailty as an independent predictor of functional outcome in patients undergoing mechanical thrombectomy. George Harston, Chief Medical & Innovation Officer at Brainomix, said: "This is an exciting study, where our next generation biomarkers were able to assess brain frailty, finding it to be a useful criterion when assessing a patient's suitability for mechanical thrombectomy and the likelihood of them achieving a good clinical outcome." This topic will be included with other breakthrough research projects in an upcoming webinar that Brainomix have organized with Dr Ansaar Rai and Dr Waleed Brinjikji on Thursday, June 12th.Brainomix supported a number of additional studies at ESOC, including:Dr Amelia Adcock ( West Virginia University ) presented the results of a comparative analysis of Brainomix 360 Stroke and Viz.ai, with the findings demonstrating that both AI solutions accurately identified intracranial LVOs. Notably, Brainomix 360 Stroke did exhibit a higher sensitivity for more distal occlusions and was the only CT perfusion solution that showed a significant association between perfusion deficit and NIHSS.( ) presented the results of a comparative analysis of Brainomix 360 Stroke and Viz.ai, with the findings demonstrating that both AI solutions accurately identified intracranial LVOs
CHICAGO, May 21, 2025 /PRNewswire/ -- The global Artificial Intelligence in Diagnostics Market Size is projected to be valued at USD 1.97 Billion in 2025 and reach USD 5.44 billion by 2030, growing at a CAGR of 22.46% according to a new report by The Research Insights. The AI In Diagnostics Market Growth is propelled by governmental programs that support Al-based technology development and startup financing along with big data increases and expanding cross-industry partnerships. The development of the market faces limitations because of insufficient Al labor availability and the absence of specific regulations for medical software.For More Information and To Stay Updated on The Latest Developments in The Artificial Intelligence in Diagnostics Market, Download the Sample Pages: https://www.theresearchinsights.com/request_sample?id=10The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the Artificial Intelligence in Diagnostics Market growth of 22.46% comprises a vast array of Component, Diagnosis and Geography which are expected to register strength during the coming years.Market Overview and Growth Trajectory:Artificial Intelligence in Diagnostics Market Growth: According to an exhaustive report by The Research Insights, the Artificial Intelligence in Diagnostics Market is experiencing significant growth, as Al-based technologies have become increasingly sought after in the diagnostics field over time because they offer immense potential for medical image diagnosis. These benefits include better imaging triage methods and clinical decision support tools while also providing faster diagnostic image analysis and more accurate interpretation of small data elements that radiologists usually miss. These tools enable radiologists to focus on enhancing patient care instead of spending time on image interpretation.For Detailed AI In Diagnostics Market Insights, Visit: https://www.theresearchinsights.com/reports/artificial-intelligence-in-diagnostics-market-10Rising Demand for Early and Accurate Disease Detection:One of the most compelling drivers of the AI in diagnostics market is the escalating need for early, precise, and efficient disease diagnosis
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced a multi-year partnership with Sanofi, an innovative global healthcare company, and Regeneron, a leading biotechnology company, to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease.
Sanofi recently entered into a multi-year partnership with Viz.ai and Regeneron to develop an AI-powered solution for COPD management, reflecting its focus on innovation. Over the last month, the company’s stock increased by 1.71%, paralleling broader market trends, which have seen modest gains amid easing trade concerns and strong corporate earnings. This stock movement coincides with Sanofi's robust Q1 earnings growth and a significant share buyback completion. The company’s announcements of acquisitions and ongoing corporate strategies have likely complemented the market's positive sentiments, contributing to the slight rise in its share price. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. ENXTPA:SAN Earnings Per Share Growth as at May 2025 Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit